Patents by Inventor Sam Bob Corveleyn

Sam Bob Corveleyn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID FORMS OF (5S)-CYCLOPROPYL-5-[3-[(3S)-4-(3,5-DIFLUOROPHENYL)-3-METHYL-PIPERAZIN-1-YL]-3-OXO-PROPYL]IMIDAZOLIDINE-2,4-DIONE
    Publication number: 20240124424
    Abstract: The present invention relates to solid forms of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3 -oxo-propyl]imidazolidine-2,4-dione and to pharmaceutical preparations comprising them and methods of their manufacture, as well as the use of said solid forms or preparations for the prophylaxis and/or treatment of inflammatory conditions, muscular disease, fibrotic diseases, viral infection, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis, especially osteoarthritis.
    Type: Application
    Filed: December 13, 2021
    Publication date: April 18, 2024
    Inventors: Renaud Henri Marcel LÉPINE, Didier Philippe Robert SCHILS, Sam Bob CORVELEYN, Michael Anthony LYNCH, Nicolas Valentin LEBLANC, Gradus Johannes DULOS
  • Prodrug Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20220281857
    Abstract: The present invention relates to prodrug compounds and their use in the treatment of Cystic Fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: May 27, 2022
    Publication date: September 8, 2022
    Inventors: Didier Philippe Robert Schils, Sam Bob Corveleyn, Herman Augustinus De Kock, Matthew Beau Dufek
  • Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
    Patent number: 11345691
    Abstract: The present invention relates to prodrug compounds and their use in the treatment of Cystic Fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: May 31, 2022
    Assignees: AbbVie Global Enterprises Ltd., Galapagos NV
    Inventors: Didier Philippe Robert Schils, Sam Bob Corveleyn, Herman Augustinus De Kock, Matthew Beau Dufek
  • Prodrug Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20200377491
    Abstract: The present invention relates to prodrug compounds and their use in the treatment of Cystic Fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: June 2, 2020
    Publication date: December 3, 2020
    Inventors: Didier Philippe Robert Schils, Sam Bob Corveleyn, Herman Augustinus De Kock, Matthew Beau Dufek